Sihuan Pharmaceutical Holdings Group Ltd. (HKEX:0460) released an announcement stating it expects revenue of no less than RMB2,500 million for the year ended 31 December 2025, marking a 30% increase year-on-year. Net profit is projected at no less than RMB150 million during the same period, reflecting strong operational performance.

Significant growth in the medical aesthetics business contributed to these preliminary results, with revenue surpassing RMB1,400 million and segment profit exceeding RMB700 million. Both figures rose over 90% compared to the previous year. Multiple self-developed products in collagen stimulators, poly-L-lactic acid, and skin boosters received regulatory approvals, enabling Sihuan Pharmaceutical to offer a full range of aesthetic solutions. Distribution channels supported rapid expansion, and the market share of botulinum toxin product Letybo increased to nearly 20%, with coverage in over 8,000 medical aesthetic institutions. Sihuan Pharmaceutical also advanced its global ambitions by signing an investment subscription agreement with a Swiss aesthetic medicine company, aiming to expand its sales coverage to 43 countries.

In the innovative drug business, subsidiaries Xuanzhu Biopharm and Huisheng Biopharm achieved noteworthy progress, including product approvals and the smooth commercialization of new drugs. Xuanzhu Biopharm completed its spin-off listing on the Main Board of the Hong Kong Stock Exchange in October 2025, providing equity appreciation gains and easing research and development funding pressures. This development, alongside multiple share repurchases and a solid cash reserve, further strengthened Sihuan Pharmaceutical’s overall financial structure and supported its efforts to boost profitability and market competitiveness.